What is the generic name?

LOVASTATIN

What is the Trade Name for LOVASTATIN?

Altoprev

What are the Indications for LOVASTATIN?

• 1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be one component of multiple risk factor intervention in individuals who require modifications of their lipid profile. Drug therapy is recommended as an adjunct to a diet restricted in saturated fat and cholesterol only when the response to diet and other non-pharmacological measures has been inadequate. Altoprev ¬Æ is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: ‚Ä¢ Reduce the risk of MI, revascularization procedures, and angina in patients without CHD, but with multiple risk factors. ( 1.1 ) ‚Ä¢ Slow the progression of coronary atherosclerosis in patients with CHD as part of a treatment strategy to lower Total-C and LDL-C. ( 1.1 ) ‚Ä¢ Reduce elevated Total-C, LDL-C, Apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Limitations of Use Altoprev ¬Æ has not been studied in Fredrickson Types I, III, and V dyslipidemias. ( 1.3 ) 1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev ¬Æ is indicated to reduce the risk of: ‚Ä¢ Myocardial infarction ‚Ä¢ Unstable angina ‚Ä¢ Coronary revascularization procedures Coronary Heart Disease Altoprev ¬Æ is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.2 Hyperlipidemia Altoprev ¬Æ is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb). 1.3 Limitations of Use Altoprev ¬Æ has not been studied in Fredrickson Types I, III, and V.

References: https://open.fda.gov/